MET amplification (at 7q21) has been identified as a mechanism of innate resistance to vemurafenib in one melanoma cell line, LM38, opening new possibilities for efficacious combinations of MET and BRAF inhibitors [73]. This evidence concerns the gene BRAF and melanoma.